trending Market Intelligence /marketintelligence/en/news-insights/trending/yonMTERRTf2Rv-uoEMCUPg2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

Gilead's Kite unit exits cancer collaboration with Alpine Immune


Global M&A Infographic Q1 2021


Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


COVID-19 Impact & Recovery: Private Equity

COVID-19 Impact & Recovery: Corporates

Gilead's Kite unit exits cancer collaboration with Alpine Immune

Alpine Immune Sciences Inc. said Gilead Sciences Inc.'s Kite Pharma Inc. unit terminated a collaboration to develop cancer immunotherapies, effective June 20.

Through the October 2015 research and license agreement, Kite was granted an exclusive license to two programs from Alpine's transmembrane immunomodulatory protein technology for applications to antigen receptor and T cell receptor products.

Under the collaboration, Kite Pharma made an up-front payment of $5 million along with additional payments to support Alpine's research. Alpine was also eligible to receive a total of $530 million in pre‐specified research, clinical and regulatory milestones.

Kite Pharma's decision was due to the expiration of the agreement's research term, Alpine Immune noted.

On May 15, Alpine Immune signed a collaboration with U.K.-based Adaptimmune Therapeutics PLC to develop immunotherapies for solid tumors.